Domainex and Imperial College London partner on heart attack treatments
October 20, 2015Research and Development Domainex cardiac arrest
Drug discovery company Domainex and Imperial College London have announced a new partnership aimed at discovering novel therapies to treat …
Synergy Vision expands global presence to meet demand in the Asia-Pacific region
October 20, 2015Medical Communications Asia-Pacific, Australia, Sydney, Synergy Vision, asia pacific, medical communcations
UK-based Synergy Vision opens a new office in Sydney, Australia, to meet the demands of their clients across the Asia-Pacific …
Recall after mislabelling of Medline Industries’ drugs
October 20, 2015Manufacturing and Production US, acetaminophen, paracetamol, product recall
Medline Industries is voluntarily carrying out a nationwide recall of the painkiller acetaminophen, due to a labelling error on the …
China’s Tianjin invests $300m in Ebola plant
October 20, 2015Manufacturing and Production China, Ebola, Ebola vaccine, manufacturing, production, vaccines
China’s Tianjin CanSino Biotechnology, a developer of affordable vaccines, says that it will invest 2 billion Yuan (£203.3 million) in …
UK ‘is the best place in the world to do big data’, says AAR lead
October 20, 2015Manufacturing and Production Accelerated Access Review, Big Data, Professor Sir John Bell
The UK is leading the world in developing new drugs from the analysis of big data, according to a leading …
Nuevolution, Johnson & Johnson begin discovery collaboration
October 19, 2015Manufacturing and Production, Research and Development Chemetics, Janssen Biotech, Nuevolution
Nuevolution and Janssen Biotech have entered into a collaboration which will use Nuevolution’s Chemetics drug discovery platform to facilitate discovery …
Regeneron to invest $350 million, create 200 jobs in Ireland
October 19, 2015Manufacturing and Production, Research and Development
US pharma company Regeneron has announced plans to invest $350 million into its production facility in Limerick, Ireland, creating 200 …
2015’s top five mergers and acquisitions in a record-breaking year
October 19, 2015Sales and Marketing Deals, acquisitions, mergers, pharma, takeovers
A new report from analysts MergerMarket reveals that mergers and acquisitions so far in 2015 have surpassed the same 2014 …
Shire’s dry eye treatment gets a no – for now
October 19, 2015Sales and Marketing Complete Response Letter, FDA, Flemming Ornskov, Shire, dry eye disease, lifitegrast
Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …
FDA approves Boehringer’s Pradaxa reversal agent
October 19, 2015Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab
The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …
Sanofi and Regeneron heart drug Praluent available in UK
October 19, 2015Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent
Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …
FDA rejects AstraZeneca diabetes combination
October 16, 2015Research and Development, Sales and Marketing AstraZeneca, FDA, NDA, dapagliflozin, saxagliptin
The FDA has declined to approve AstraZeneca’s New Drug Application (NDA) for the investigational fixed-dose combination of Onglyza and and …
Pfizer’s Xeljanz denied plaque psoriasis indication by FDA
October 16, 2015Research and Development, Sales and Marketing FDA, Pfizer, Xeljanj, tofacitinib
The FDA has rejected the indication expansion of Pfizer’s Xeljanz (tofacitinib) for treatment of moderate to severe cases of plaque psoriasis. …
Top 10 US pharma advertising spenders, September 2015
October 16, 2015Medical Communications, Sales and Marketing
As a new study from TV advertising metrics company iSpot reveals the top 40 pharma companies spent $231 million on TV …
NICE to recommend three new treatments for hep C
October 16, 2015Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C
NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …
Ashfield UK makes two new business development appointments for its growing team
October 16, 2015Medical Communications Ashfield UK
Ashfield has appointed David Tweedale and Ian Robinson as Business Development Managers to the UK Commercial and Clinical business, located …
The Prime Medical Group expands senior team in New York City
October 16, 2015Medical Communications
The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …
Health apps now more popular than ever in the UK
October 16, 2015Medical Communications apps, digital pharma, health technology, technology
The use of health apps has considerably increased over the past years, according to a new survey that has found …
NICE requests more evidence on Duchenne muscular dystrophy therapy
October 16, 2015Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PCT Therapeutics, Translarna, ataluren
NICE has chosen not to recommend has PTC Therapeutics’ treatment Translarna for Duchenne muscular dystrophy (DMD), asking for further clarification …
The Prime Medical Group expands senior team in New York City
October 15, 2015Medical Communications The Prime Medical Group
The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
